Investors

Press Releases

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

September 3, 2019

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

August 30, 2019

Geneva, Switzerland and Boston, MA – August 30, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13- 14, 2019

August 9, 2019

Geneva, Switzerland and Boston, MA – August 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

August 7, 2019

Geneva, Switzerland and Boston, MA – August 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more

ObsEva Reports Second Quarter 2019 Financial Results

August 7, 2019

    Multiple Major Milestones Expected This Year Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban Nolasiban MAA…

Read more

ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019

August 5, 2019

Geneva, Switzerland and Boston, MA – August 5, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more

ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022

July 26, 2019

Geneva, Switzerland and Boston, MA – July 26, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

July 18, 2019

Geneva, Switzerland and Boston, MA – July 18, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more

ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban

July 17, 2019

Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019   GENEVA, Switzerland and BOSTON, MA…

Read more

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City

July 17, 2019

Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.